CD8-depleted DLIs and GVHD
| Patient no., DLI . | GVHD after CD8-depleted DLI . | |||
|---|---|---|---|---|
| Organ . | OG . | Start, d . | Comment . | |
| 3 | ||||
| 1st | None | NA | NA | None |
| 2nd | Skin | I | 24 | Short-term CsA: CR |
| 3rd | None | NA | NA | None |
| 4* | ||||
| 1st | Skin, gut, liver | III | 59 | FK506, MMF, steroids: limited cGVHD |
| 5 | ||||
| 1st | None | NA | NA | None |
| 2nd | Skin | I | 21 | Short-term CsA: CR |
| 8 | ||||
| 1st | Skin | I | 40 | Topical steroids: CR |
| 9* | ||||
| 1st | Skin, liver | II | 21 | CsA, steroids: limited cGVHD |
| 10 | ||||
| 1st | None | NA | NA | None |
| 2nd | None | NA | NA | None |
| 3rd | None | NA | NA | None |
| 11 | ||||
| 1st | None | NA | NA | None |
| 14 | ||||
| 1st | None | NA | NA | None |
| 2nd | None | NA | NA | None |
| 3rd | None | NA | NA | None |
| 4th | None | NA | NA | None |
| 15 | ||||
| 1st | Skin | I | 13 | No therapy: CR |
| 2nd | None | NA | NA | None |
| 17 | ||||
| 1st | Skin | I | 16 | Topical steroids: CR |
| 18 | ||||
| 1st | None | NA | NA | None |
| 2nd | None | NA | NA | None |
| Patient no., DLI . | GVHD after CD8-depleted DLI . | |||
|---|---|---|---|---|
| Organ . | OG . | Start, d . | Comment . | |
| 3 | ||||
| 1st | None | NA | NA | None |
| 2nd | Skin | I | 24 | Short-term CsA: CR |
| 3rd | None | NA | NA | None |
| 4* | ||||
| 1st | Skin, gut, liver | III | 59 | FK506, MMF, steroids: limited cGVHD |
| 5 | ||||
| 1st | None | NA | NA | None |
| 2nd | Skin | I | 21 | Short-term CsA: CR |
| 8 | ||||
| 1st | Skin | I | 40 | Topical steroids: CR |
| 9* | ||||
| 1st | Skin, liver | II | 21 | CsA, steroids: limited cGVHD |
| 10 | ||||
| 1st | None | NA | NA | None |
| 2nd | None | NA | NA | None |
| 3rd | None | NA | NA | None |
| 11 | ||||
| 1st | None | NA | NA | None |
| 14 | ||||
| 1st | None | NA | NA | None |
| 2nd | None | NA | NA | None |
| 3rd | None | NA | NA | None |
| 4th | None | NA | NA | None |
| 15 | ||||
| 1st | Skin | I | 13 | No therapy: CR |
| 2nd | None | NA | NA | None |
| 17 | ||||
| 1st | Skin | I | 16 | Topical steroids: CR |
| 18 | ||||
| 1st | None | NA | NA | None |
| 2nd | None | NA | NA | None |
OG, overall grade of GVHD; d, day (after DLI) of first diagnosis of GVHD; NA, not applicable; CsA, cyclosporine A; CR, complete remission of GVHD; FK506, tacrolimus; MMF, mycophenolate mofetil.
Patient with GVHD before DLI (in both cases, skin, OG I, transient).